Navigation Links
EORTC presents European solution for effective cancer drug development
Date:7/1/2014

Drug developers are facing the perfect storm. They are confronted with major patent expiries, increased payer scrutiny, changing priorities, shifting business models, increased risk averseness, increased clinical trial costs, not to mention issues concerning R&D productivity. There needs to be a better way to identify new candidate drugs. There needs to be a new drug development pathway that is compatible with research aimed at understanding the biology of a cancer and simultaneously able to support the design and conduct of subsequent confirmatory trials, but building and maintaining such a drug development pathway is beyond the ability of individual organizations or companies. It has been argued that new forms of partnership as well as an integrated model of cancer research are needed. Now, in a paper published in Nature Reviews Clinical Oncology, the EORTC describes how collaborative molecular screening platforms could help serve these needs.

Collaborative molecular screening platforms offer a high quality integrated infrastructure for efficient screening of patients with cancer for specific molecular alterations. These identified alterations will define target populations for early trials with novel targeted agents. Pharmaceutical industry partners would be in a position to propose candidate drugs for clinical trials which could be plugged into the platform. Patients fulfilling the inclusion criteria for one or more trials would be notified by their physician and given the option of participating.

Dr. Denis Lacombe, EORTC Director and lead author of this paper says, "Collaborative molecular screening platforms will offer patients efficient access to new therapeutic agents. Clinical research will be turned on its head. Instead of designing trials which must find patients for a particular drug, the question will become which drug should be given to a particular subset of patients with an identified molecular alteration."

Co
'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EORTC to present cancer research results at ASCO 2014
2. NCI, NCRI and EORTC outline risk-assessment approach for biomarker-driven cancer clinical trials
3. EORTC and SIOG update expert opinion on management of elderly patients with NSCLC
4. EORTC study shows value of HRQOL assessment in small cell lung cancer
5. Joint EORTC-ESTRO session to focus on current developments in soft tissue sarcoma treatment
6. EORTC Cancer in the Elderly Task Force investigates appropriate treatment for elderly patients
7. EORTC head & neck cancer trial shows assessing HRQOL is valuable to both patients and their doctors
8. Sequential GO and chemotherapy no benefit for older AML patients according to EORTC/GIMEMA trial
9. Vaccination with GM2-KLH-QS21 does not improve outcome of melanomas patients in EORTC study
10. EORTC at 2013 ECCO-ESMO-ESTRO meeting in Amsterdam
11. Moderate dose radiotherapy effective in EORTC trial for patients with desmoid-type fibromatosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... HealthDay Reporter TUESDAY, ... such as Adderall, Ritalin and Concerta -- used to ... growth, a new study suggests. "Stimulant medication did ... researcher Dr. Slavica Katusic, an associate professor of pediatrics ... noted that results of earlier studies have been mixed, ...
(Date:9/2/2014)... (HealthDay News) -- Drinking and marijuana may lead to ... study suggests. Researchers analyzed 2007 to 2011 data ... who said they had used alcohol or marijuana at ... was associated with more unsafe driving, damage to relationships ... while under the influence of alcohol, especially among females. ...
(Date:9/2/2014)... ALEXANDRIA, VAThe latest research on sleep apnea, tonsillectomies, ... otolaryngic topics will be presented in Orlando, FL, ... OTO EXPO℠ of the American Academy of OtolaryngologyHead ... meeting of ear, nose, throat, head and neck ... research to be presented were released today, and ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated compression ... a luxurious line of graduated compression socks with natural fibers. ... Socks are joining the SIGVARIS MEDICAL collection for those who ... of natural cotton fibers. , “When people step into ... socks as soft as the finest cashmere,” says Clay Walker, ...
(Date:9/2/2014)... September 02, 2014 The exclusive ClinicCRM ... was designed to help doctors manage foreign patient flow, ... patient conversion rates and clink revenue. Since its launch ... increase in sales revenue and a 70 percent increase ... in their own healthcare practices. , With its ease ...
Breaking Medicine News(10 mins):Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 2Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4
... ... ... ... ...
... ... ... ... ...
... CREST trial that compared traditional surgery with less-invasive stenting ... is being called "seminal and robust." The Carotid ... safety and efficacy of both procedures are roughly equal. ... is one of the largest randomized stroke prevention trials ...
... , ... California Dental Hygienists’ Association Conducts Statewide Outreach Efforts to Provide Low-Income Children Access ... ... National Children’s Dental Health Month draws to a close, California’s dental hygienists ...
... ago, researchers say, , FRIDAY, Feb. 26 (HealthDay News) -- ... than 12,000 years ago, new research suggests. , The researchers ... a major determinant of small size in dogs. The gene ... the Middle Eastern gray wolf, according to the study, published ...
... newcomers hold mettle against warfarin, aspirin , FRIDAY, Feb. ... that the mainstays of anti-clotting therapy, namely warfarin and ... , Researchers presenting their findings during a Friday news ... San Antonio show that one new drug, dabigatran (Pradaxa), ...
Cached Medicine News:Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 2Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 3Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 4Health News:American National Announces Corrected Dividend Dates 2Health News:Stents as good as surgery for clogged carotid arteries 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 3Health News:Current Blood Thinners Face Tough Competition 2Health News:Current Blood Thinners Face Tough Competition 3
(Date:9/2/2014)... , España, September 2, 2014 ... de fibrilación atrial muestran agentes antitrombóticos no utilizados ... -- Las presentaciones de GARFIELD-AF en ... el tratamiento y los resultados de pacientes en ... diaria --    Los datos de ...
(Date:9/2/2014)... , September 2, 2014 ... ESC CONGRESS 2014 provide insight into treatment and ... everyday clinical practice --   Data ... Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an ... stroke prevention strategies for atrial fibrillation (AF) patients ...
(Date:9/2/2014)... 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... of the company at the Morgan Stanley Global Healthcare Conference ... Presentation date: Tuesday September 9, 2014 , Presentation time: ... and 30-day archive of this presentation will be available at ... Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... Langan, Vice President of Marketing and Business Development, announced ... labeling for sterile intravenous compounded ICU Services at ... May 19-24, 2012 in Orlando, Florida. (Logo: ... care professionals to visit Booth #2668 to see how ...
...  Varian Medical Systems (NYSE: VAR ) will ... and other conditions non-invasively at the 2012 International Conference ... in San Francisco.  "We,re excited about ... not be familiar with radiosurgery as a treatment option ...
Cached Medicine Technology:PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 3Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: